Human SUMO3 MAb (Clone 907614)

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: SUMO3

Small Ubiquitin­like Modifiers (SUMOs) are a family of small, related proteins that can be enzymatically attached to a target protein by a post­translational modification process termed SUMOylation. Unlike ubiquitination, which targets proteins for degradation, SUMOylation participates in a number of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. All human SUMO proteins share a conserved ubiquitin-like domain and a C-terminal diglycine cleavage/attachment site. Human SUMO3, also known as SMT3A, is synthesized as a 103 amino acid (aa), 11.5 kDa propeptide that contains an 11 aa C­terminal prosegment. Following prosegment cleavage, the C­terminal glycine may be enzymatically attached to a lysine on a target protein. Human SUMO3 shares 83% sequence identity with SUMO3 from mouse. SUMO3 also has very high sequence homology to SUMO2 and SUMO4, 87% and 75%, respectively. SUMO3 shares only 47% sequence identity to SUMO1.

Product Datasheets

Related Research Areas

• NFkB Pathway
• Ubiquitin-like Modifiers (UBLs) and Regulators